$INFU
InfuSystem Holdings, Inc

2022 Q4 Form 10-Q Financial Statement

#000162828022028855 Filed on November 08, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $28.83M $27.28M
YoY Change 8.71% 2.68%
Cost Of Revenue $12.75M $11.06M
YoY Change 13.74% -2.19%
Gross Profit $16.08M $16.22M
YoY Change 5.03% 6.3%
Gross Profit Margin 55.79% 59.46%
Selling, General & Admin $14.69M $14.66M
YoY Change 17.37% 1.3%
% of Gross Profit 91.31% 90.4%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $3.104M $3.440M
YoY Change -15.1% -8.02%
% of Gross Profit 19.3% 21.21%
Operating Expenses $15.05M $15.28M
YoY Change 9.8% -2.13%
Operating Profit $1.029M $943.0K
YoY Change -35.77% -368.66%
Interest Expense -$426.0K $385.0K
YoY Change -8.97% 42.59%
% of Operating Profit -41.4% 40.83%
Other Income/Expense, Net -$53.00K -$11.00K
YoY Change 47.22% -75.0%
Pretax Income $550.0K $547.0K
YoY Change -49.91% -182.26%
Income Tax $443.0K $104.0K
% Of Pretax Income 80.55% 19.01%
Net Earnings $107.0K $443.0K
YoY Change -72.35% -198.88%
Net Earnings / Revenue 0.37% 1.62%
Basic Earnings Per Share $0.02
Diluted Earnings Per Share $0.01 $0.02
COMMON SHARES
Basic Shares Outstanding 20.66M shares 20.69M shares
Diluted Shares Outstanding 21.45M shares

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $165.0K $363.0K
YoY Change -11.29% 120.0%
Cash & Equivalents $165.0K $363.0K
Short-Term Investments
Other Short-Term Assets $2.922M $2.311M
YoY Change 15.27% 7.44%
Inventory $4.821M $4.861M
Prepaid Expenses
Receivables $16.87M $16.11M
Other Receivables $0.00 $0.00
Total Short-Term Assets $24.78M $23.65M
YoY Change 12.3% 8.15%
LONG-TERM ASSETS
Property, Plant & Equipment $4.385M $4.211M
YoY Change -3.05% -4.86%
Goodwill $3.710M $3.710M
YoY Change 0.0% 0.0%
Intangibles $8.436M $8.805M
YoY Change -22.82% -26.18%
Long-Term Investments
YoY Change
Other Assets $80.00K $2.181M
YoY Change -83.01% 953.62%
Total Long-Term Assets $74.61M $75.33M
YoY Change -1.21% 3.31%
TOTAL ASSETS
Total Short-Term Assets $24.78M $23.65M
Total Long-Term Assets $74.61M $75.33M
Total Assets $99.39M $98.98M
YoY Change 1.85% 4.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.341M $6.648M
YoY Change 6.09% -0.82%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $14.47M $12.73M
YoY Change 12.18% -12.09%
LONG-TERM LIABILITIES
Long-Term Debt $33.16M $34.46M
YoY Change 1.25% 12.77%
Other Long-Term Liabilities $3.761M $3.979M
YoY Change 2.48% 21.05%
Total Long-Term Liabilities $33.16M $34.46M
YoY Change 1.25% 12.77%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.47M $12.73M
Total Long-Term Liabilities $33.16M $34.46M
Total Liabilities $51.39M $51.17M
YoY Change 4.2% 5.88%
SHAREHOLDERS EQUITY
Retained Earnings -$59.34M -$59.35M
YoY Change 10.09% 38.02%
Common Stock $2.000K $2.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $48.00M $47.81M
YoY Change
Total Liabilities & Shareholders Equity $99.39M $98.98M
YoY Change 1.85% 4.43%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income $107.0K $443.0K
YoY Change -72.35% -198.88%
Depreciation, Depletion And Amortization $3.104M $3.440M
YoY Change -15.1% -8.02%
Cash From Operating Activities $4.566M $3.456M
YoY Change 23.04% -40.32%
INVESTING ACTIVITIES
Capital Expenditures $4.053M -$4.018M
YoY Change -163.29% -19.24%
Acquisitions
YoY Change
Other Investing Activities $1.001M $516.0K
YoY Change 28.83% -6.35%
Cash From Investing Activities -$3.052M -$3.502M
YoY Change -45.76% -20.84%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.712M 98.00K
YoY Change -188.38% -107.17%
NET CHANGE
Cash From Operating Activities 4.566M 3.456M
Cash From Investing Activities -3.052M -3.502M
Cash From Financing Activities -1.712M 98.00K
Net Change In Cash -198.0K 52.00K
YoY Change -1042.86% 5100.0%
FREE CASH FLOW
Cash From Operating Activities $4.566M $3.456M
Capital Expenditures $4.053M -$4.018M
Free Cash Flow $513.0K $7.474M
YoY Change -94.93% -30.58%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
infu Medical Equipment Increase In Pump Reserve
MedicalEquipmentIncreaseInPumpReserve
600000 usd
dei Local Phone Number
LocalPhoneNumber
291-1210
infu Depreciation Expense Related To Medical Equipment
DepreciationExpenseRelatedToMedicalEquipment
7300000 usd
dei Entity Central Index Key
EntityCentralIndexKey
0001337013
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35020
dei Entity Registrant Name
EntityRegistrantName
INFUSYSTEM HOLDINGS, INC
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-3341405
dei Entity Address Address Line1
EntityAddressAddressLine1
3851 West Hamlin Road
dei Entity Address City Or Town
EntityAddressCityOrTown
Rochester Hills
dei Entity Address State Or Province
EntityAddressStateOrProvince
MI
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
48309
dei City Area Code
CityAreaCode
248
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
INFU
dei Security Exchange Name
SecurityExchangeName
NYSEAMER
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
20656374 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
363000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
186000 usd
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
16112000 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
15405000 usd
CY2022Q3 us-gaap Inventory Net
InventoryNet
4861000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
3939000 usd
CY2022Q3 us-gaap Other Assets Current
OtherAssetsCurrent
2311000 usd
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2535000 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
23647000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
22065000 usd
CY2022Q3 infu Medical Equipment Held For Sale Or Rental
MedicalEquipmentHeldForSaleOrRental
2843000 usd
CY2021Q4 infu Medical Equipment Held For Sale Or Rental
MedicalEquipmentHeldForSaleOrRental
1742000 usd
CY2022Q3 infu Medical Equipment In Rental Service Net Of Accumulated Depreciation
MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation
39202000 usd
CY2021Q4 infu Medical Equipment In Rental Service Net Of Accumulated Depreciation
MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation
39871000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4211000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4523000 usd
CY2022Q3 us-gaap Goodwill
Goodwill
3710000 usd
CY2021Q4 us-gaap Goodwill
Goodwill
3710000 usd
CY2022Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
8805000 usd
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
10930000 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4441000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4241000 usd
CY2022Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
9941000 usd
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
10033000 usd
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2181000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
471000 usd
CY2022Q3 us-gaap Assets
Assets
98981000 usd
CY2021Q4 us-gaap Assets
Assets
97586000 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
6648000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7862000 usd
CY2022Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 usd
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
349000 usd
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
6086000 usd
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4685000 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
12734000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12896000 usd
CY2022Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
34461000 usd
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
32748000 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3979000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3670000 usd
CY2022Q3 us-gaap Liabilities
Liabilities
51174000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
49314000 usd
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
97586000 usd
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20670049 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20670049 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20699546 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20699546 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
2000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
2000 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
105557000 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
101905000 usd
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1599000 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
268000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-59351000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-53903000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
47807000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
48272000 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
98981000 usd
CY2021Q3 infu Depreciation Expense Related To Medical Equipment
DepreciationExpenseRelatedToMedicalEquipment
2400000 usd
CY2022Q3 us-gaap Revenues
Revenues
27279000 usd
CY2021Q3 us-gaap Revenues
Revenues
26566000 usd
us-gaap Revenues
Revenues
81084000 usd
us-gaap Revenues
Revenues
75863000 usd
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
11060000 usd
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
11308000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
34597000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
30979000 usd
CY2022Q3 us-gaap Gross Profit
GrossProfit
16219000 usd
CY2021Q3 us-gaap Gross Profit
GrossProfit
15258000 usd
us-gaap Gross Profit
GrossProfit
46487000 usd
us-gaap Gross Profit
GrossProfit
44884000 usd
CY2022Q3 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-90000 usd
CY2021Q3 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
10000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-84000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-99000 usd
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
704000 usd
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1125000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2125000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3264000 usd
CY2022Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2894000 usd
CY2021Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2908000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
9296000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
7964000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11768000 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11566000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
34525000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
32537000 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
15276000 usd
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
15609000 usd
us-gaap Operating Expenses
OperatingExpenses
45862000 usd
us-gaap Operating Expenses
OperatingExpenses
43666000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
943000 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-351000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
625000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
1218000 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
385000 usd
CY2021Q3 us-gaap Interest Expense
InterestExpense
270000 usd
us-gaap Interest Expense
InterestExpense
976000 usd
us-gaap Interest Expense
InterestExpense
909000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-11000 usd
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-44000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-69000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-150000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
547000 usd
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-665000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-420000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
159000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
104000 usd
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-217000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-331000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-874000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
443000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-448000 usd
us-gaap Net Income Loss
NetIncomeLoss
-89000 usd
us-gaap Net Income Loss
NetIncomeLoss
1033000 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.02
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.05
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.02
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
infu Depreciation Expense Related To Medical Equipment
DepreciationExpenseRelatedToMedicalEquipment
7000000 usd
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.05
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20683366 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20577886 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20625826 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20468842 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21452483 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20577886 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20625826 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21995216 shares
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
443000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-448000 usd
us-gaap Net Income Loss
NetIncomeLoss
-89000 usd
us-gaap Net Income Loss
NetIncomeLoss
1033000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Before Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent
605000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Before Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent
41000 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Before Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent
1754000 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Before Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent
93000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent
146000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent
10000 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent
423000 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent
23000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
902000 usd
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-417000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1242000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1103000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
44700000 usd
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
38000 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1955000 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
179000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
31000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-448000 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
46455000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
46497000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
212000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1066000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
192000 usd
CY2022Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
59000 usd
CY2022Q3 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
1003000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
459000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
443000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
47807000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
40752000 usd
us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
431000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4962000 usd
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
348000 usd
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1141000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
70000 usd
us-gaap Net Income Loss
NetIncomeLoss
1033000 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
46455000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
48272000 usd
us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
685000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3236000 usd
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
428000 usd
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
697000 usd
us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
5359000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1331000 usd
us-gaap Net Income Loss
NetIncomeLoss
-89000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
47807000 usd
us-gaap Net Income Loss
NetIncomeLoss
-89000 usd
us-gaap Net Income Loss
NetIncomeLoss
1033000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-84000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-99000 usd
us-gaap Depreciation
Depreciation
8131000 usd
us-gaap Depreciation
Depreciation
7705000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3300000 usd
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
1450000 usd
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
848000 usd
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
1348000 usd
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
1588000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2125000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3264000 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
55000 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
132000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
3236000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
4962000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-331000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-875000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
607000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-217000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
922000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
630000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-224000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-251000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
89000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
102000 usd
us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
1200000 usd
us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
-513000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
12951000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
14605000 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
7650000 usd
infu Payments To Acquire Medical Equipment
PaymentsToAcquireMedicalEquipment
10452000 usd
infu Payments To Acquire Medical Equipment
PaymentsToAcquireMedicalEquipment
9645000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
571000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
607000 usd
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
2597000 usd
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
2214000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-8426000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-15688000 usd
us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
31089000 usd
us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
69306000 usd
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
32398000 usd
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
61654000 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
386000 usd
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
750000 usd
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
0 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
698000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1141000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
5359000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1150000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
779000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-4348000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-8400000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
177000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9483000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
186000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9648000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
363000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
165000 usd
us-gaap Basis Of Accounting
BasisOfAccounting
Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies<div style="margin-top:12pt;padding-right:7.2pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The terms “InfuSystem”, the “Company”, “we”, “our” and “us” are used herein to refer to InfuSystem Holdings, Inc. and its subsidiaries. InfuSystem is a leading provider of infusion pumps and related products and services for patients in the home, oncology clinics, ambulatory surgery centers, and other sites of care. The Company provides products and services to hospitals, oncology practices and facilities and other alternative site health care providers. Headquartered in Rochester Hills, Michigan, the Company delivers local, field-based customer support, and also operates pump service and repair Centers of Excellence in Michigan, Kansas, California, Massachusetts, Texas and Ontario, Canada.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, the unaudited condensed consolidated financial statements do not include all of the information and notes required by U.S. Generally Accepted Accounting Principles (“GAAP”) for complete financial statements. The accompanying unaudited condensed consolidated financial statements include all adjustments, composed of normal recurring adjustments, considered necessary by management to fairly state the Company’s results of operations, financial position and cash flows. The operating results for the interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 as filed with the SEC on March 15, 2022.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The unaudited condensed consolidated financial statements are prepared in conformity with GAAP, which requires the use of estimates, judgments and assumptions that affect the amounts of assets and liabilities at the reporting date and the amounts of revenue and expenses in the periods presented. The Company believes that the accounting estimates employed are appropriate and the resulting balances are reasonable; however, due to the inherent uncertainties in making estimates, actual results could differ from the original estimates, requiring adjustments to these balances in future periods.</span></div>
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
7650000 usd
infu Working Capital
WorkingCapital
325000 usd
us-gaap Business Combination Consideration Transferred Liabilities Incurred
BusinessCombinationConsiderationTransferredLiabilitiesIncurred
750000 usd
us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
8725000 usd
CY2022Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
725000 usd
CY2022Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Inventory
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
74000 usd
CY2022Q3 infu Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Medical Equipment Held For Sale Or Rental
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalEquipmentHeldForSaleOrRental
40000 usd
CY2022Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
161000 usd
CY2022Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
4015000 usd
CY2022Q3 us-gaap Goodwill
Goodwill
3710000 usd
CY2022Q3 infu Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Operating Lease Right Of Use Asset
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAsset
288000 usd
CY2022Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Capital Lease Obligation
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation
288000 usd
CY2022Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
8725000 usd
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
200000 usd
CY2022Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangibles
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
4015000 usd
us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P11Y2M12D
CY2022Q3 infu Medical Equipment Held For Sale Or Rental Gross
MedicalEquipmentHeldForSaleOrRentalGross
2865000 usd
CY2021Q4 infu Medical Equipment Held For Sale Or Rental Gross
MedicalEquipmentHeldForSaleOrRentalGross
1788000 usd
CY2021Q3 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
26566000 usd
us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
76633000 usd
CY2021Q3 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-373000 usd
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
1268000 usd
CY2022Q3 us-gaap Revenues
Revenues
27279000 usd
CY2021Q3 us-gaap Revenues
Revenues
26566000 usd
us-gaap Revenues
Revenues
81084000 usd
us-gaap Revenues
Revenues
75863000 usd
CY2022Q3 infu Medical Equipment For Sale Or Rental Reserve
MedicalEquipmentForSaleOrRentalReserve
22000 usd
CY2021Q4 infu Medical Equipment For Sale Or Rental Reserve
MedicalEquipmentForSaleOrRentalReserve
46000 usd
CY2022Q3 infu Medical Equipment Held For Sale Or Rental
MedicalEquipmentHeldForSaleOrRental
2843000 usd
CY2021Q4 infu Medical Equipment Held For Sale Or Rental
MedicalEquipmentHeldForSaleOrRental
1742000 usd
CY2022Q3 infu Medical Equipment In Rental Services Gross
MedicalEquipmentInRentalServicesGross
97021000 usd
CY2021Q4 infu Medical Equipment In Rental Services Gross
MedicalEquipmentInRentalServicesGross
91891000 usd
CY2022Q3 infu Medical Equipment In Rental Services Reserve
MedicalEquipmentInRentalServicesReserve
2074000 usd
CY2021Q4 infu Medical Equipment In Rental Services Reserve
MedicalEquipmentInRentalServicesReserve
1074000 usd
CY2022Q3 infu Medical Equipment In Rental Services Accumulated Depreciation
MedicalEquipmentInRentalServicesAccumulatedDepreciation
55745000 usd
CY2021Q4 infu Medical Equipment In Rental Services Accumulated Depreciation
MedicalEquipmentInRentalServicesAccumulatedDepreciation
50946000 usd
CY2022Q3 infu Medical Equipment In Rental Service Net Of Accumulated Depreciation
MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation
39202000 usd
CY2021Q4 infu Medical Equipment In Rental Service Net Of Accumulated Depreciation
MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation
39871000 usd
CY2022Q3 infu Medical Equipment Net
MedicalEquipmentNet
42045000 usd
CY2021Q4 infu Medical Equipment Net
MedicalEquipmentNet
41613000 usd
CY2022Q3 infu Depreciation Expense Related To Medical Equipment
DepreciationExpenseRelatedToMedicalEquipment
2400000 usd
CY2022Q3 infu Medical Equipment Increase In Pump Reserve
MedicalEquipmentIncreaseInPumpReserve
100000 usd
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8864000 usd
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4653000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4211000 usd
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8366000 usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3843000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4523000 usd
CY2022Q3 us-gaap Depreciation Nonproduction
DepreciationNonproduction
300000 usd
us-gaap Depreciation Nonproduction
DepreciationNonproduction
800000 usd
CY2021Q3 us-gaap Depreciation Nonproduction
DepreciationNonproduction
200000 usd
us-gaap Depreciation Nonproduction
DepreciationNonproduction
700000 usd
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0 usd
CY2022Q3 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
2000000 usd
CY2022Q3 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
2000000 usd
CY2021Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
2000000 usd
CY2021Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
2000000 usd
CY2022Q3 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
53802000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
44997000 usd
CY2022Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
8805000 usd
CY2021Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
53802000 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
42872000 usd
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
10930000 usd
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
700000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2100000 usd
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1100000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
369000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
990000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
990000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
810000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
524000 usd
CY2022Q3 infu Amortization Expense Year Five And Thereafter
AmortizationExpenseYearFiveAndThereafter
3122000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
6805000 usd
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
0 usd
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
0 usd
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
0 usd
CY2022Q3 infu Long Term Debt Maturities Repayments Of Principal Year Four And Thereafter
LongTermDebtMaturitiesRepaymentsOfPrincipalYearFourAndThereafter
34706000 usd
CY2022Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
34706000 usd
CY2022Q3 infu Longterm Debt Gross Current
LongtermDebtGrossCurrent
0 usd
CY2022Q3 infu Long Term Debt Gross Noncurrent
LongTermDebtGrossNoncurrent
34706000 usd
CY2022Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
34706000 usd
CY2021Q4 infu Longterm Debt Gross Current
LongtermDebtGrossCurrent
423000 usd
CY2021Q4 infu Long Term Debt Gross Noncurrent
LongTermDebtGrossNoncurrent
32974000 usd
CY2021Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
33397000 usd
CY2022Q3 infu Unamortized Debt Issuance Expense Current
UnamortizedDebtIssuanceExpenseCurrent
0 usd
CY2022Q3 infu Unamortized Debt Issuance Expense Noncurrent
UnamortizedDebtIssuanceExpenseNoncurrent
245000 usd
CY2022Q3 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
245000 usd
CY2021Q4 infu Unamortized Debt Issuance Expense Current
UnamortizedDebtIssuanceExpenseCurrent
74000 usd
CY2021Q4 infu Unamortized Debt Issuance Expense Noncurrent
UnamortizedDebtIssuanceExpenseNoncurrent
226000 usd
CY2021Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
300000 usd
CY2022Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 usd
CY2022Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
34461000 usd
CY2022Q3 us-gaap Long Term Debt
LongTermDebt
34461000 usd
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
349000 usd
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
32748000 usd
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
33097000 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
400000 usd
CY2021Q3 us-gaap Interest Expense
InterestExpense
300000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
443000 usd
us-gaap Interest Expense
InterestExpense
1000000 usd
us-gaap Interest Expense
InterestExpense
900000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
100000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-300000 usd
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-200000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-900000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-448000 usd
us-gaap Net Income Loss
NetIncomeLoss
-89000 usd
us-gaap Net Income Loss
NetIncomeLoss
1033000 usd
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20683366 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20577886 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20625826 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20468842 shares
CY2022Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
769117 shares
CY2021Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1526374 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21452483 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20577886 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20625826 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21995216 shares
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.02
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.05
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.02
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.05
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1143001 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
300000 shares
CY2021Q2 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
20000000 usd
CY2022Q3 infu Share Repurchase Program Cumulative Shares Repurchased
ShareRepurchaseProgramCumulativeSharesRepurchased
5900000 usd
CY2022Q3 infu Share Repurchase Program Cumulative Shares Purchased Shares
ShareRepurchaseProgramCumulativeSharesPurchasedShares
517672 shares
CY2022Q3 us-gaap Lessor Operating Lease Term Of Contract
LessorOperatingLeaseTermOfContract
P10Y
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
342000 usd
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
302000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
1006000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
998000 usd
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
77000 usd
CY2021Q3 us-gaap Variable Lease Cost
VariableLeaseCost
65000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
231000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
180000 usd
CY2022Q3 us-gaap Lease Cost
LeaseCost
419000 usd
CY2021Q3 us-gaap Lease Cost
LeaseCost
367000 usd
us-gaap Lease Cost
LeaseCost
1237000 usd
us-gaap Lease Cost
LeaseCost
1178000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
946000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
993000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
18000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
288000 usd
infu Increases To Right Of Use Assets Resulting From Lease Modifications
IncreasesToRightOfUseAssetsResultingFromLeaseModifications
1050000 usd
infu Increases To Right Of Use Assets Resulting From Lease Modifications
IncreasesToRightOfUseAssetsResultingFromLeaseModifications
0 usd
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y10M24D
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y3M18D
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.071
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.077
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
303000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1159000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1064000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1033000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
998000 usd
CY2022Q3 infu Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
2841000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
7398000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2451000 usd
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
4947000 usd
CY2022Q3 infu Lessee Operating Lease Lease Not Yet Commenced Minimum Payment
LesseeOperatingLeaseLeaseNotYetCommencedMinimumPayment
1800000 usd
CY2022Q3 us-gaap Lessee Finance Lease Remaining Lease Term
LesseeFinanceLeaseRemainingLeaseTerm
P7Y
CY2022Q3 infu Revenues External
RevenuesExternal
27279000 usd
CY2022Q3 infu Revenues Internal
RevenuesInternal
0 usd
CY2022Q3 us-gaap Revenues
Revenues
27279000 usd
CY2022Q3 us-gaap Gross Profit
GrossProfit
16219000 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
15276000 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
385000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-11000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
104000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
443000 usd
CY2022Q3 us-gaap Assets
Assets
98981000 usd
CY2022Q3 infu Payments To Acquire Medical Equipment
PaymentsToAcquireMedicalEquipment
3783000 usd
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3440000 usd
CY2021Q3 infu Revenues External
RevenuesExternal
26566000 usd
CY2021Q3 infu Revenues Internal
RevenuesInternal
0 usd
CY2021Q3 us-gaap Revenues
Revenues
26566000 usd
CY2021Q3 us-gaap Gross Profit
GrossProfit
15258000 usd
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
15609000 usd
CY2021Q3 us-gaap Interest Expense
InterestExpense
270000 usd
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-44000 usd
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-217000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-448000 usd
CY2021Q3 us-gaap Assets
Assets
94786000 usd
CY2021Q3 infu Payments To Acquire Medical Equipment
PaymentsToAcquireMedicalEquipment
4702000 usd
CY2021Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3740000 usd
infu Revenues External
RevenuesExternal
81084000 usd
infu Revenues Internal
RevenuesInternal
0 usd
us-gaap Revenues
Revenues
81084000 usd
us-gaap Gross Profit
GrossProfit
46487000 usd
us-gaap Operating Expenses
OperatingExpenses
45862000 usd
us-gaap Interest Expense
InterestExpense
976000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-69000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-331000 usd
us-gaap Net Income Loss
NetIncomeLoss
-89000 usd
CY2022Q3 us-gaap Assets
Assets
98981000 usd
infu Payments To Acquire Medical Equipment
PaymentsToAcquireMedicalEquipment
10452000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
10256000 usd
infu Revenues External
RevenuesExternal
75863000 usd
infu Revenues Internal
RevenuesInternal
0 usd
us-gaap Revenues
Revenues
75863000 usd
us-gaap Gross Profit
GrossProfit
44884000 usd
us-gaap Operating Expenses
OperatingExpenses
43666000 usd
us-gaap Interest Expense
InterestExpense
909000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-150000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-874000 usd
us-gaap Net Income Loss
NetIncomeLoss
1033000 usd
CY2021Q3 us-gaap Assets
Assets
94786000 usd
infu Payments To Acquire Medical Equipment
PaymentsToAcquireMedicalEquipment
9645000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
10969000 usd

Files In Submission

Name View Source Status
0001628280-22-028855-index-headers.html Edgar Link pending
0001628280-22-028855-index.html Edgar Link pending
0001628280-22-028855.txt Edgar Link pending
0001628280-22-028855-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
infu-20220930.htm Edgar Link pending
infu-20220930.xsd Edgar Link pending
infu-20220930xexx3111.htm Edgar Link pending
infu-20220930xexx3121.htm Edgar Link pending
infu-20220930xexx3211.htm Edgar Link pending
infu-20220930xexx3221.htm Edgar Link pending
infu-20220930_g1.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
infu-20220930_lab.xml Edgar Link unprocessable
infu-20220930_cal.xml Edgar Link unprocessable
infu-20220930_pre.xml Edgar Link unprocessable
infu-20220930_def.xml Edgar Link unprocessable
infu-20220930_htm.xml Edgar Link completed
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending